Product Description
Estrone is a female sex hormone. The weakest type of estrogen, it's typically higher after menopause. Like all estrogen, estrone supports female sexual development and function. Low or high estrone can cause symptoms such as irregular bleeding, fatigue or mood swings. (Sourced from: https://my.clevelandclinic.org/health/body/22398-estrone)
Mechanisms of Action: ER Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | Korea | New Zealand | Pakistan | Portugal | Taiwan | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/19/2025 |
News Article |
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease |
|
11/03/2025 |
News Article |
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition |
|
10/17/2025 |
News Article |
Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia |
|
09/04/2025 |
News Article |
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia |